My research focuses on the pathogenesis and therapeutic strategies of atopic dermatitis (AD) and related skin inflammatory diseases. I have extensively investigated the role of antimicrobial peptides (AMPs), such as human β-defensin-3 and AMP-IBP5, in modulating skin barrier function, autophagy, and immune responses. One of the core strengths of my work lies in elucidating novel signaling pathways—such as the aryl hydrocarbon receptor and Notch1/PKC axis—through which AMPs exert protective effects in AD models. Additionally, I have contributed to the identification of diagnostic markers and potential therapeutic targets like betacellulin and S100A7. My approach integrates molecular biology, animal models, and clinical data, offering translational insights. A distinctive aspect of my research is the discovery of new AMP-based mechanisms that regulate skin inflammation and barrier integrity, paving the way for future peptide-based therapeutics.